Stifel Financial’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Stifel Financial’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,000	Closed	-$7K	–	3154
2019 Q3	$7K	Hold	10,000	–	–	﹤0.01%	2847
2019 Q2	$8K	Hold	10,000	–	–	﹤0.01%	2953
2019 Q1	$12K	Hold	10,000	–	–	﹤0.01%	2784
2018 Q4	$8K	Hold	10,000	–	–	﹤0.01%	2655
2018 Q3	$30K	Hold	10,000	–	–	﹤0.01%	2718
2018 Q2	$37K	Hold	10,000	–	–	﹤0.01%	2676
2018 Q1	$35K	Hold	10,000	–	–	﹤0.01%	2647
2017 Q4	$31K	Hold	10,000	–	–	﹤0.01%	2607
2017 Q3	$70K	Hold	10,000	–	–	﹤0.01%	2499
2017 Q2	$92K	Hold	10,000	–	–	﹤0.01%	2461
2017 Q1	$107K	Buy	+10,000	New	+$102K	﹤0.01%	2424

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Stifel Financial's NVLN Position: Q4 2019 in Review

Stifel Financial sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 10,000 shares — an estimated $7K sold.

Stifel Financial first reported a position in NVLN in Q1 2017 and held it in 11 quarters. The position peaked at $107K in Q1 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

Stifel Financial reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
Stifel Financial sold 10,000 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $7K.
Stifel Financial first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 11 quarters.
Stifel Financial's Novelion Therapeutics Inc. Common Shares position peaked at $107K in Q1 2017.
7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Stifel Financial's 13F filing for Q4 2019, filed 13 Feb 2020.